1983
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher R, DeVita V, Hubbard S, Longo D, Wesley R, Chabner B, Young R. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Annals Of Internal Medicine 1983, 98: 304-9. PMID: 6600902, DOI: 10.7326/0003-4819-98-3-304.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBlood PlateletsCyclophosphamideDoxorubicinDrug Administration ScheduleDrug Therapy, CombinationEtoposideFemaleHumansLeucovorinLeukopeniaLymphomaMaleMechlorethamineMethotrexateMiddle AgedPrednisoneProcarbazineVincristineConceptsComplete remission rateDiffuse aggressive lymphomasMOPP chemotherapyRemission rateAggressive lymphomaDose-limiting toxicityRelapse-free survivalNew treatment programPhases of treatmentComplete remissionComplete respondersMedian durationMedian survivalUntreated patientsTumor responsePatient rateLate intensificationPatientsAdvanced stageChemotherapyTreatment programSurvivalLymphoma
1973
Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu)
Young R, Walker M, Canellos G, Schein P, Chabner B, Devita V. Initial clinical trials with methyl‐ccnu 1‐(2‐chloroethyl)‐3‐(4‐methyl cyclohexyl)‐1‐nitrosourea (meccnu). Cancer 1973, 31: 1164-1169. PMID: 4705154, DOI: 10.1002/1097-0142(197305)31:5<1164::aid-cncr2820310519>3.0.co;2-4.Peer-Reviewed Original ResearchConceptsPrior therapyMultiple dosesClinical trialsCumulative marrow toxicityObjective therapeutic responseHepatic side effectsSingle oral doseReticulum cell sarcomaInitial clinical trialsPrimary brain tumorsPreliminary clinical trialsMarrow suppressionHodgkin's diseaseOral doseCell sarcomaMarrow toxicityPrimary toxicityTherapeutic responseBrain tumorsSide effectsPatientsConsiderable toxicitySubsequent courseMeCCNUDoses
1972
Delayed hypersensitivity in Hodgkin's disease A study of 103 untreated patients
Young R, Corder M, Haynes H, DeVita V. Delayed hypersensitivity in Hodgkin's disease A study of 103 untreated patients. The American Journal Of Medicine 1972, 52: 63-72. PMID: 5058359, DOI: 10.1016/0002-9343(72)90008-3.Peer-Reviewed Original ResearchConceptsSkin test reactivityPeripheral lymphocyte countTest reactivityHodgkin's diseaseLymphocyte countUntreated patientsPrognostic signSkin testAbsolute peripheral lymphocyte countLymphocyte-depleted Hodgkin's diseaseMean absolute lymphocyte countIncidence of anergyStage IV diseaseAbsolute lymphocyte countBad prognostic signDuration of remissionFrequency of relapsesTime of diagnosisStage of diseaseUseful prognostic signCutaneous anergyPeripheral lymphocytopeniaMixed cellularityMumps antigenNodular sclerosis
1971
Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU
Young R, DeVita V, Serpick A, Canellos G. Treatment of Advanced Hodgkin's Disease with [1,3 Bis (2-Chloroethyl)-L-Nitrosourea] BCNU. New England Journal Of Medicine 1971, 285: 475-479. PMID: 5558887, DOI: 10.1056/nejm197108262850902.Peer-Reviewed Original Research
1970
Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease
LOWENBRAUN S, DEVITA V, SERPICK A. Combination Chemotherapy With Nitrogen Mustard, Vincristine, Procarbazine and Prednisone in Previously Treated Patients With Hodgkin's Disease. Blood 1970, 36: 704-717. PMID: 5488687, DOI: 10.1182/blood.v36.6.704.704.Peer-Reviewed Original ResearchConceptsCombination chemotherapyPrior radiotherapyHodgkin's diseaseProgressive Hodgkin's diseaseStage IV diseaseRemission 1Previous therapyComplete responseNitrogen mustardPartial responseTherapy completionSystemic symptomsDrug combinationsChemotherapyPatientsDay 1Drug AdministrationRadiotherapyPrednisoneDiseasePoor toleranceVincristineCycle 1TherapyI.V.Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma
Lowenbraun S, DeVita V, Serpick A. Combination chemotherapy with nitrogen mustard, vincristine, procarbazine, and prednisone in lymphosarcoma and reticulum cell sarcoma. Cancer 1970, 25: 1018-1025. PMID: 4910254, DOI: 10.1002/1097-0142(197005)25:5<1018::aid-cncr2820250505>3.0.co;2-a.Peer-Reviewed Original ResearchConceptsReticulum cell sarcomaComplete remissionPartial remissionRCS patientsCell sarcomaLSA patientsUnmaintained complete remissionOnset of therapyCombination of agentsGeneralized lymphosarcomaModerate myelosuppressionCombination chemotherapyRC patientsTherapy completionMean durationPatientsRemissionLymphosarcomaSarcomaVincristineDiseaseNitrogen mustardSurvivalSubstantial durationDuration
1968
Severe vinblastine-induced leukopenia during late pregnancy with delivery of a normal infant.
Nordlund J, DeVita V, Cabbone P. Severe vinblastine-induced leukopenia during late pregnancy with delivery of a normal infant. Annals Of Internal Medicine 1968, 69: 581-2. PMID: 5673176, DOI: 10.7326/0003-4819-69-3-581.Peer-Reviewed Original ResearchAdultAnaphylaxisAntitoxinsClostridium InfectionsDelivery, ObstetricFemaleFetusHodgkin DiseaseHumansInfant, NewbornLeukopeniaPenicillinsPregnancyPregnancy ComplicationsPregnancy Complications, HematologicPregnancy Complications, InfectiousProteus InfectionsPuerperal InfectionSepsisSteroidsVinblastine